CDDP induces p53-dependent apoptosis in tongue cancer cells

Int J Oncol. 2000 Sep;17(3):513-7. doi: 10.3892/ijo.17.3.513.


We have investigated the CDDP sensitivities of two tongue cancer cell lines with differing p53 genetic status, one with wild-type p53 (SAS) and the other with mutant-type p53 (HSC-4). SAS was about 2 times more sensitive at the D10 dose and demonstrated increased p53 and Bax protein levels at 10 h after CDDP treatment on Western blot analysis. On the other hand, overexpression of p53 in HSC-4 was observed without CDDP treatment and no elevation of Bax could be detected. Apoptosis was observed after CDDP treatment in SAS but not in HSC-4 by Hoechst 33342-staining and electrophoresis methods. These findings indicate that p53 plays an important role in apoptosis as a positive regulator of Bax expression. It is suggested that p53 status may have predictive potential with regard to response to CDDP therapy.

Publication types

  • Comparative Study

MeSH terms

  • Apoptosis / drug effects*
  • Carcinoma, Squamous Cell / genetics
  • Carcinoma, Squamous Cell / pathology*
  • Cisplatin / pharmacology*
  • DNA, Neoplasm / genetics
  • Drug Resistance, Neoplasm
  • Genes, p53
  • Humans
  • Neoplasm Proteins / biosynthesis
  • Neoplasm Proteins / physiology*
  • Polymerase Chain Reaction
  • Polymorphism, Single-Stranded Conformational
  • Proto-Oncogene Proteins / biosynthesis
  • Proto-Oncogene Proteins c-bcl-2*
  • Tongue Neoplasms / genetics
  • Tongue Neoplasms / pathology*
  • Tumor Cells, Cultured / drug effects
  • Tumor Cells, Cultured / pathology
  • Tumor Suppressor Protein p53 / biosynthesis
  • Tumor Suppressor Protein p53 / physiology*
  • bcl-2-Associated X Protein


  • BAX protein, human
  • DNA, Neoplasm
  • Neoplasm Proteins
  • Proto-Oncogene Proteins
  • Proto-Oncogene Proteins c-bcl-2
  • Tumor Suppressor Protein p53
  • bcl-2-Associated X Protein
  • Cisplatin